Big Pharma manages symptoms. This startup resolves the root cause.
For over 125 years, inflammation care has relied on symptom suppression.
Aspirin was groundbreaking in its time — but in a world plagued by chronic inflammation — we all need something better.
Sen-Jam is pioneering the first true leapfrog advance in inflammatory care.
Q: What do cancer, heart disease, and rheumatoid arthritis have in common? A: Inflammation drives them all.
Inflammation is a silent epidemic, at the core of countless chronic diseases. Yet today’s treatments only mask symptoms or worse suppress the body’s immune system, leaving the root cause untouched.
Sen-Jam changes that.
With its revolutionary PAIR (Pleiotropic Anti-Inflammatory Remedies) technology, Sen-Jam comprehensively targets inflammation at its source, delivering the most transformative advance since aspirin was invented.
This isn’t just an improvement—it’s a paradigm shift.
How does Sen-Jam work?
Most therapies target single inflammatory pathways — like fighting a wildfire with a squirt gun 🔥🔫
PAIR acts like a maestro, coordinating multiple inflammatory pathways for additive, powerful results.
In a Phase 2 clinical trial for SJP-002C, PAIR demonstrated:
Strong efficacy in treating respiratory inflammation
An exceptional safety profile, addressing both symptoms and roo causes.
“Our approach is so simple and powerful, it’s like discovering the next aspirin — an essential solution that changes everything.
Why invest in Sen-Jam?
Massive TAM: Inflammation underlies a wide range of diseases, driving a $125 billion market projected by 2030.
Unprecedented Innovation: 60 patents strong, Sen-Jam’s groundbreaking platform is positioned to disrupt the $1.48T pharma industry.
Past successful exits: Backed by a team of scientific experts and entrepreneurial veterans with a proven track record.
“This is the inflection point. Science, timing, and market demand have aligned for the biggest advance in 125 years.
